Irodalom:
H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, H. Schramm, J. Fahlke, C. Zuelke,
C. Burkart, K. Gutberlet, E. Kettner, H. Schmalenberg, K. Weigang-Koehler, W.-O. Bechstein, M. Niedergethmann, I.
Schmidt-Wolf, L. Roll, B. Doerken, and H. Riess: Adjuvant Chemotherapy With Gemcitabine vs Observation in
Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA,
January 17, 2007; 297: 267 – 277.
4
A hasnyálmirigy 447
J. A. Wallace, G. Locker, S. Nattam, K. Kasza, K. Wade-Oliver, W. M. Stadler, E. E. Vokes, H. L. Kindler:
Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of
Chicago Phase II Consortium ASCO Meeting Abstracts Jun 20 2007: 4608.
L. K. Heilbrun, A. Khanna, R. Venkatramanamoorthy, A. F. Shields, P. A. Philip, M. M. Zalupski, and
B. F. El-Rayes: CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with
gemcitabine and cisplatin based chemotherapy ASCO Meeting Abstracts, Jun 2007; 25: 15094.
H. L. Kindler, D. Niedzwiecki, D. Hollis, E. Oraefo, D. Schrag, H. Hurwitz, H. L. McLeod, M. F. Mulcahy,
R. L. Schilsky, R. M. Goldberg: Cancer and Leukemia Group B A double-blind, placebo-controlled, randomized
phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts)
with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
ASCO Meeting Abstracts Jun 20 2007: 4508.
D. Schrag, L. Archer, X. Wang, D. Romanus, M. Mulcahy, R. Goldberg, H: Kindler, for the Cancer and
Leukemia Group B (CALGB) Patterns-of-care study of post-progression treatment (Rx) among patients (pts)
with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB)
study #80303 ASCO Meeting Abstracts Jun 20 2007: 4524.
A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, D. Wong, J. Allen, M. A: Tempero A
phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and
bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study
accrual ASCO Meeting Abstracts Jun 20 2007: 4548.
G. P. Kim, A. L. Oberg, N. R. Foster, A. Jaslowski, P. J. Flynn, D. Campbell, E. Hedrick, L. Gray, A.
Grothey, S. Alberts: Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic
adenocarcinoma ASCO Meeting Abstracts Jun 20 2007: 4553.
P. A. Philip, J. Benedetti, C. Fenoglio-Preiser, M. Zalupski, H. Lenz, E. O’Reilly, R. Wong, J. Atkins, J.
Abruzzese, C. Blanke: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients
[pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study ASCO Meeting
Abstracts Jun 20 2007: 4509.
S. Cascinu, R. Berardi, S. Siena, R. Labianca, A. Falcone, E. Aitini, S. Barni, F. Di Costanzo, L. Frontini,
G. Tonini, A. Zaniboni: The impact of cetuximab on the gemcitabine/cisplatin combination in first-line
treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD ASCO
Meeting Abstracts Jun 20 2007: 4544.
M. J. Moore, D. Goldstein, J. Hamm: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone
in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical
Trials Group JCO May 20 2007: 1960-1966.
Eric Van Cutsem, Chris Verslype, Patrick A. Grusenmeyer: Lessons Learned in the Management of
Advanced Pancreatic Cancer JCO May 20 2007: 1949-1952.
T. Herrmann, D. Jaeger, W. Stremmel, and C. Herrmann: Second-line chemotherapy in advanced pancreatic
cancer: A retrospective, single-center analysis ASCO Meeting Abstracts, Jun 2007; 25: 15187.
S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner,
M. Stauch, F. Lordick, Y. Ko, M. Geissler, K. Schoppmeyer, G. Kojouharoff, A. Golf, S. Neugebauer, and V.
Heinemann: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus
gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced
pancreatic cancer Ann. Onc., Oct 2007;
B. A. Burtness, M. Powell, J. Berlin, D. Liles, A. Chapman, E. Mitchell, A. B. Benson, and Eastern
Cooperative Oncology Group: Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with
randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the
epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology ASCO Meeting Abstracts, Jun 2007;
25: 4519.
448 Gastro Update 2008
J Taïeb, T Lecomte, T Aparicio, A Asnacios, T Mansourbakht, P Artru, D Fallik, JP Spano, B Landi, G
Lledo, and J Desrame: FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for
advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist
Oncologist Association) multicenter phase II study Ann. Onc., March 2007; 18: 498 – 503.
M. Ychou, F. Desseigne, R. Guimbaud, M. Ducreux, O. Bouché, Y. Bécouarn, A. Adenis, C. MontotoGrillot,
E. Luporsi, and T. Conroy: Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV],
irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma
(MPA). First results of the ACCORD 11 trial ASCO Meeting Abstracts, Jun 2007; 25: 4516.
M. Reni, S. Cereda, P. Passoni, A. Rognone, E. Mazza, R. Nicoletti, P. G. Arcidiacono, A. Zerbi, G. Balzano,
V. Di Carlo: A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG
(docetaxel) regimen in advanced pancreatic adenocarcinoma ASCO Meeting Abstracts Jun 20 2007: 4628.
Hideki Ueno, Takuji Okusaka, Masafumi Ikeda, Chigusa Morizane, Takashi Ogura, Atsushi Hagihara,
and Tsutomu Tanaka: Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for
Patients with Metastatic Pancreatic Cancer Jpn. J. Clin. Oncol., July 2007; 37: 515 – 520.
Asma Sultana, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P.: Neoptolemos, and
Paula Ghaneh. Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer J.
Clin. Oncol., Jun 2007; 25: 2607 – 2615.
M. H. Kulke, L.S. Blaszkowsky, D.P. Ryan et al: Capecitabine Plus Erlotinib in Gemcitabine-Refractory
Advanced Pancreatic Cancer JCO Oct 20 2007: 4787-4792.
M. Blaya, G. L. Lopes, Jr, E. Roman, E. Ahn, J. Macintyre, J. Quesada, J. Levi, G. Walker, M. Green,
C. M. Rocha: Lima Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and
metastatic pancreatic cancer ASCO Meeting Abstracts Jun 20 2007: 15029.
S. H. Boeck, R. Wilkowski, C. J. Bruns, R. D. Issels, C. Schulz, N. Moosmann, D. Laessig, A. Golf, V.
Heinemann: Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer: A singlecenter
study ASCO Meeting Abstracts Jun 20 2007: 15085.
S Boeck, K Weigang-Köhler, M Fuchs, E Kettner, D Quietzsch, J Trojan, O Stötzer, S Zeuzem, F Lordick,
C-H Köhne, H Kröning, T Steinmetz, H Depenbrock, and V Heinemann: Second-line chemotherapy with pemetrexed
after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial Ann.
Onc., April 2007; 18: 745 – 751.
V Gebbia, E Maiello, F Giuliani, N Borsellino, M Caruso, G Di Maggio, F Ferraù, R Bordonaro, F
Verderame, P Tralongo, L Di Cristina, R Agueli, P Russo, and G Colucci: Second-line chemotherapy in
advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity
and safety of the FOLFOX4 regimen in clinical practice Ann. Onc., June 2007; 18: vi124 – vi127.
A. Mancuso, S. Sacchetta, P. Saletti, C. Tronconi, L. Milesi, M. Garassino, O. Martelli, R. Labianca, F.
Cavalli, C. N. Sternberg: Clinical and molecular determinants of survival in pancreatic cancer patients treated
with second line chemotherapy: results of an Italian/Swiss multicenter survey ASCO Meeting Abstracts Jun 20
2007: 4622.
L. S. Blaszkowsky, D. P. Ryan, C. Earle, E. Kwak, C. Fuchs, J. A. Meyerhardt, K. Stuart, A. X. Zhu, P.
Enzinger, M. H. Kulke: A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously
treated patients with metastatic pancreatic cancer ASCO Meeting Abstracts Jun 20 2007: 15080.
A. Astsaturov, N. J. Meropol, R. K. Alpaugh, J. D. Cheng, N. L. Lewis, M. Beard, A. Rogatko, Z. Xu, L. M.
Weiner, S. J. Cohen:A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients
with previously treated metastatic pancreatic adenocarcinoma ASCO Meeting Abstracts Jun 20 2007: 4556.
A. C. Berger, K. Winter, J. Hoffman, W. Regine, R. Abrams, H. Safran, A. Konski, A. Benson, III, J.
MacDonald, C. Willet: Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant
chemoradiation: A secondary endpoint of RTOG 9704 ASCO Meeting Abstracts Jun 20 2007: 4522.
A hasnyálmirigy 449
Kohei Nakachi, Junji Furuse, Hiroshi Ishii, Ei-ichiro Suzuki, and Masahiro Yoshino:Prognostic Factors
in Patients with Gemcitabine-Refractory Pancreatic Cancer Jpn. J. Clin. Oncol., February 2007; 37: 114 – 120.
M. Mandalà, M. Reni, S. Cascinu, S. Barni, I. Floriani, S. Cereda, R. Berardi, S. Mosconi, V. Torri, and
R. Labianca: Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
Ann. Onc., October 2007; 18: 1660 – 1665.
Stephen A. Welch and Malcolm J. Moore: Combination Chemotherapy in Advanced Pancreatic Cancer:
Time to Raise the White Flag? J. Clin. Oncol., Jun 2007; 25: 2159 – 2161.
C Verslype, E Van Cutsem, M Dicato, S Cascinu, D Cunningham, E Diaz-Rubio, B Glimelius, D Haller,
K Haustermans, V Heinemann, P Hoff, PG Johnston, D Kerr, R Labianca, C Louvet, B Minsky, M Moore, B
Nordlinger, S Pedrazzoli, A Roth, M Rothenberg, P Rougier, H-J Schmoll, J Tabernero, M Tempero, C van de
Velde, J-L Van Laethem, and J Zalcberg: The management of pancreatic cancer. Current expert opinion and
recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006 Ann. Onc.,
June 2007; 18: vii1 – vii10.
